Best Tests for Inherited Cholesterol Risk

A total cholesterol result of 280 mg/dL can be a warning. So can an LDL-C of 165 mg/dL that has been dismissed for years as “a little high.” But numbers alone do not reveal whether the problem is diet-sensitive, metabolically driven, or inherited. The best tests for inherited cholesterol identify the pattern behind the lab value - and, just as importantly, show whether that pattern has already begun to affect the arteries.

For proactive adults with a parent who had a heart attack early, a sibling on a statin in their 30s, or a personal history of stubbornly elevated cholesterol, this is not a wellness question. It is a precision prevention question. The goal is to identify inherited cardiovascular risk before plaque, symptoms, or an emergency forces the issue.

When High Cholesterol May Be Inherited

Familial hypercholesterolemia, often called FH, is the best-known inherited cholesterol disorder. It usually involves genetic variants that reduce the body's ability to clear LDL particles from the bloodstream. The result can be markedly elevated LDL-C from an early age and lifelong exposure to artery-damaging cholesterol.

Classic FH is not the only concern. Many people inherit a polygenic tendency toward higher LDL cholesterol, higher triglycerides, elevated lipoprotein(a), or a combination of lipid and metabolic risks. A routine annual physical may flag an abnormal result, but it often cannot distinguish among these possibilities.

Suspicion rises when untreated LDL-C is 190 mg/dL or higher, though lower values can still matter, especially with a strong family history. A heart attack, stroke, bypass procedure, or sudden cardiac death in a first-degree relative before age 55 in men or 65 in women also warrants a closer look. So does an LDL-C that remains high despite a thoughtful diet, regular exercise, and healthy body composition.

Best Tests for Inherited Cholesterol: Start With Advanced Lipids

A standard lipid panel measures total cholesterol, LDL-C, HDL-C, and triglycerides. It is an appropriate starting point, but not the finish line when inherited risk is possible. Advanced lipid testing adds precision biomarkers that can clarify how many atherogenic particles are circulating and what may be driving risk.

ApoB: The Particle Count That Matters

Apolipoprotein B, or ApoB, estimates the number of cholesterol-containing particles capable of entering the artery wall. Each LDL particle carries one ApoB molecule, as do other atherogenic remnants. In practical terms, ApoB can reveal risk that LDL-C alone understates.

This distinction matters because two people can have the same LDL-C but very different particle counts. Someone with elevated ApoB has more opportunities for particles to penetrate the arterial lining, where they can contribute to plaque formation. ApoB is especially valuable when triglycerides are elevated, insulin resistance is present, or LDL-C and the clinical picture do not seem to match.

Lipoprotein(a): A Commonly Missed Inherited Risk

Lipoprotein(a), or Lp(a), is largely determined by genetics and is not meaningfully lowered by lifestyle changes. It is an LDL-like particle with additional properties that may promote atherosclerosis and calcific aortic valve disease. Most adults should have Lp(a) measured at least once, and earlier testing is particularly useful when there is premature heart disease in the family.

An elevated Lp(a) does not mean a cardiac event is inevitable. It does mean the rest of the risk profile deserves more deliberate management. LDL particle burden, blood pressure, glucose regulation, inflammation, smoking exposure, and existing plaque become more consequential when this inherited marker is high.

Non-HDL Cholesterol and Triglycerides

Non-HDL cholesterol captures all atherogenic cholesterol particles, not only LDL. It is easily calculated from a standard panel and can be useful when triglycerides are elevated. Triglycerides themselves are not a direct test for FH, but persistently high levels may point toward inherited combined lipid disorders, insulin resistance, alcohol sensitivity, or other cardiometabolic contributors.

Advanced lipid testing should be interpreted as a pattern. A high LDL-C with high ApoB and elevated Lp(a) suggests a different prevention strategy than high LDL-C with lower ApoB and no measurable plaque. Precision comes from connecting the numbers rather than reacting to one isolated result.

Genetic Testing for Familial Hypercholesterolemia

Genetic testing can look for pathogenic variants associated with familial hypercholesterolemia, most commonly in genes affecting LDL receptor function. A positive result can provide clarity, strengthen the case for early treatment, and help guide cascade screening for relatives.

Cascade screening means testing close family members after an inherited condition is identified. Because parents, siblings, and children may share the same genetic risk, this is one of the few cardiovascular evaluations that can protect an entire family, not just one patient.

Still, genetic testing has limits. A negative panel does not erase inherited risk. Some people have polygenic high cholesterol, variants not included on a panel, or a clinical phenotype of FH without an identifiable mutation. This is why a genetic result should be read alongside untreated lipid history, family history, physical findings, and imaging when appropriate.

Genetic testing is most helpful when LDL-C has been very high from a young age, when there is premature cardiovascular disease in the family, or when confirming a diagnosis would change how relatives are evaluated. It can also offer needed clarity to people who have been told for years that their cholesterol is simply a lifestyle issue.

Imaging Answers the Question Blood Tests Cannot

Bloodwork estimates exposure and inherited susceptibility. Imaging assesses whether disease is present now. For adults with inherited cholesterol concerns, that distinction can change the urgency and intensity of a prevention plan.

Coronary Artery Calcium Scoring

A coronary artery calcium, or CAC, scan detects calcified plaque in the coronary arteries. It is quick, does not require contrast, and can be particularly useful for appropriately selected adults who are uncertain about treatment intensity or have a family history that standard risk calculators undervalue.

A CAC score of zero is reassuring, but it is not a lifetime guarantee. It also does not detect noncalcified plaque, and younger adults may have meaningful inherited risk before calcium appears. In a person with clearly severe LDL elevation or genetically confirmed FH, a zero score should inform the conversation, not automatically end it.

Coronary CT Angiography

Coronary CT angiography, or CCTA, provides a more detailed look at both calcified and noncalcified plaque. It uses contrast and is not necessary for everyone. However, it can be a powerful next step when symptoms, a concerning family history, markedly abnormal biomarkers, or an unclear CAC result call for a closer view of coronary anatomy.

The trade-off is straightforward: CCTA offers more anatomical detail but involves contrast, radiation exposure, and a more involved evaluation than CAC scoring. The right study depends on age, risk profile, kidney function, symptoms, and what unanswered question the imaging is meant to resolve.

A Practical Testing Sequence

For many asymptomatic adults, the most efficient evaluation begins with a detailed personal and family history plus a repeat fasting or nonfasting lipid panel, depending on the clinical question. The next layer is usually ApoB, Lp(a), non-HDL cholesterol, triglycerides, blood sugar markers, liver and thyroid assessment, and blood pressure review. These tests help separate inherited lipid disorders from secondary causes that can raise cholesterol.

If the pattern suggests FH or another inherited disorder, genetic testing may be appropriate. If the question is whether decades of exposure have translated into silent coronary plaque, CAC scoring or CCTA can provide the missing evidence. There is no single “best” test for every person. The best approach is the combination that identifies inherited risk, measures particle burden, and establishes whether arterial disease is already developing.

What to Do With an Abnormal Result

An elevated ApoB, Lp(a), LDL-C, or genetic finding should lead to a risk-reduction strategy, not panic. The details may include nutrition and exercise, but inherited cholesterol often requires more than lifestyle optimization. Medication can be a central tool for lowering lifelong atherogenic particle exposure, especially in familial hypercholesterolemia or when imaging shows plaque.

The key is to avoid two common mistakes: assuming a healthy lifestyle cancels a genetic lipid disorder, or starting treatment without understanding the full risk picture. A specialist-led cardiometabolic prevention consultation can organize advanced bloodwork, genetic data, family history, and coronary imaging into one individualized plan.

At Precardion Heart Health, the purpose of advanced testing is not to generate more data for its own sake. It is to create clarity before the first symptom - and to give you a precise, defensible plan for protecting the years ahead.